Social Media Icons

   

You are here

Biopharmaceutical Integrated Marketing
CLIENT:
Ferro Pfanstiehl Laboratories, Inc. (Wholly-owned subsidiary of Ferro Corporation)
Impactful visual identity was first used in this trade ad.

The client needed an attention-grabbing visual identity to introduce and dramatize the advantages of its ICH-Q7A-compliant sugars for stabilizing freeze-dried therapeutic proteins used in injectable biopharmaceutical drugs. Existing regulations for excipients dated from biopharm's infancy and only required manufacturing practices tailored to oral guidelines. But most protein-based biopharm drugs must be injected—which should demand a much higher level of purity.

The central images of a syringe contrasted against a spoonful of sugar-coated cereal and the headline that focused on safety concerns created a memorable identity. Ad copy stresses that competitors' sugars are Ferro Pfanstiehl's raw materials. Risks associated with "qualified" food-grade sugars are cited, along with benefits of the new injectable-quality carbohydrates.    

Trade show display graphics catch the eye on a crowded show floor, with graphs and bullet copy to reinforce the message.

The client needed an attention-grabbing visual identity to introduce and dramatize the advantages of its ICH-Q7A-compliant sugars for stabilizing freeze-dried therapeutic proteins used in injectable biopharmaceutical drugs. Existing regulations for excipients dated from biopharm's infancy and only required manufacturing practices tailored to oral guidelines. But most protein-based biopharm drugs must be injected—which should demand a much higher level of purity.

The central images of a syringe contrasted against a spoonful of sugar-coated cereal and the headline that focused on safety concerns created a memorable identity. Ad copy stresses that competitors' sugars are Ferro Pfanstiehl's raw materials. Risks associated with "qualified" food-grade sugars are cited, along with benefits of the new injectable-quality carbohydrates.    

The graphic is compelling even on a banner stand, which is ideal for small conferences attended by the client's key audiences.

The client needed an attention-grabbing visual identity to introduce and dramatize the advantages of its ICH-Q7A-compliant sugars for stabilizing freeze-dried therapeutic proteins used in injectable biopharmaceutical drugs. Existing regulations for excipients dated from biopharm's infancy and only required manufacturing practices tailored to oral guidelines. But most protein-based biopharm drugs must be injected—which should demand a much higher level of purity.

The central images of a syringe contrasted against a spoonful of sugar-coated cereal and the headline that focused on safety concerns created a memorable identity. Ad copy stresses that competitors' sugars are Ferro Pfanstiehl's raw materials. Risks associated with "qualified" food-grade sugars are cited, along with benefits of the new injectable-quality carbohydrates.    

A peer-reviewed article resulted in an invitation for the client to join an FDA panel.

Media follow-up calls for the product launch press release garnered a request from BioPharm for an article exploring the regulatory gaps for excipients used in injectable biopharmaceutical drugs. The peer-reviewed article resulted in an invitation for the client to join an FDA panel providing input on new regulations. As a result, the client's HPLE carbohydrates' purity and endotoxin levels were written into USP compendial specifications. [ read the article ]